Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences

Cancer Gene Therapy

Volumn 23, Issue 6, 2016, Pages 178-187

  Chaurasiya, S ^a   Hew, P ^b   Crosley, P ^a   Sharon, D ^c   Potts, K ^a   Agopsowicz, K ^a   Long, M ^d   Shi, C ^e   Hitt, M M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Medpace ^*  (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DUAL SPECIFICITY PHOSPHATASE 2; INTERLEUKIN 2; LUCIFERASE; MAMMAGLOBIN; MAMMAGLOBIN PROMOTER ENHANCER 2; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; SECRETOGLOBIN; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENHANCER REGION; FEMALE; HUMAN; HUMAN CELL; LIVER TOXICITY; MOUSE; MURINE CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY SEQUENCE; REPORTER GENE; TISSUE SPECIFICITY; VIRAL GENE THERAPY; ADENOVIRIDAE; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENHANCER ELEMENTS, GENETIC; FEMALE; GENE EXPRESSION; GENES, REPORTER; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; MICE; PROMOTER REGIONS, GENETIC; SECRETOGLOBINS; TELOMERASE; TUMOR BURDEN;

EID: 84965025913     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.18     Document Type: Article

References (57)

1. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE et al. Clinical cancer advances 2011: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2012; 30: 88-109.
2. Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology (Williston Park) 2008; 22: 614-623; discussion 623, 627-619.
3. Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 2008; 8: 224-233.
4. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121: 3786-3788.
5. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
6. Amer MH. Gene therapy for cancer: present status and future perspective. Mol Cell Ther 2014; 2: 27.
7. Alvarez M, Bouchlaka MN, Sckisel GD, Sungur CM, Chen M, Murphy WJ. Increased antitumor effects using IL-2 with anti-TGF-beta reveals competition between mouse NK and CD8 T cells. J Immunol 2014; 193: 1709-1716.
8. Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-beta pathway for cancer therapy. Clin Cancer Res 2012; 18: 4514-4521.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
10. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11-22.
11. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004; 28: 109-123.
12. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004; 10: 6342S-6346S.
13. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002; 29: 12-17.
14. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 Suppl 1: S55-S57.
15. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 37: 117-132.
16. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008; 57: 931-950.
17. Davis CB, Gillies SD. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 2003; 52: 297-308.
18. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996; 93: 7826-7831.
19. Penichet ML, Dela Cruz JS, Shin SU, Morrison SL. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum Antibodies 2001; 10: 43-49.
20. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res 1998; 58: 1478-1485.
21. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 2006; 15: 179-185.
22. Sadeghi H, Hitt MM. Transcriptionally targeted adenovirus vectors. Curr Gene Ther 2005; 5: 411-427.
23. Bramson JL, Hitt M, Gauldie J, Graham FL. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Therapy 1997; 4: 1069-1076.
24. Goedegebuure PS, Watson MA, Viehl CT, Fleming TP. Mammaglobin-based strategies for treatment of breast cancer. Curr Cancer Drug Targets 2004; 4: 531-542.
25. Watson MA, Dintzis S, Darrow CM, Voss LE, DiPersio J, Jensen R et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 1999; 59: 3028-3031.
26. Shi CX, Long MA, Liu L, Graham FL, Gauldie J, Hitt MM. The human SCGB2A2 (mammaglobin-1) promoter/enhancer in a helper-dependent adenovirus vector directs high levels of transgene expression in mammary carcinoma cells but not in normal nonmammary cells. Mol Ther 2004; 10: 758-767.
27. Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Therapy 1998; 5: 1656-1664.
28. Shi CX, Graham FL, Hitt MM. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breastcancer-specific mammaglobin promoter. J Gene Med 2006; 8: 442-451.
29. Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT et al. Smallmolecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2006; 2: 543-550.
30. Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK, Hergenrother PJ. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3. J Med Chem 2009; 52: 5721-5731.
31. Addison CL, Hitt M, Kunsken D, Graham FL. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.
32. Desilva A, Wuest M, Wang M, Hummel J, Mossman K, Wuest F et al. Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT. Am J Nucl Med Mol Imaging 2012; 2: 88-98.
33. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802-8806.
34. Putzer BM, Bramson JL, Addison CL, Hitt M, Siegel PM, Muller WJ et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther 1998; 9: 707-718.
35. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-8526.
36. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8: 137-142.
37. Hitt MM, Bett AJ, Prevec L, Graham FL. Construction and Propagation of Human Adenovirus Vectors. Academic Press: New York, 1994.
38. Cen H, Mao F, Aronchik I, Fuentes RJ, Firestone GL. DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. FASEB J 2008; 22: 2243-2252.
39. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol 2005; 42: 405-426.
40. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001; 61: 5796-5802.
41. Wack S, Rejiba S, Parmentier C, Aprahamian M, Hajri A. Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther 2008; 16: 252-260.
42. Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 1998; 5: 1400-1409.
43. Coventry BJ, Ashdown ML. The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 2012; 4: 215-221.
44. Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ. Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res 1996; 56: 507-510.
45. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003; 95: 741-749.
46. Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C et al. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med 2013; 11: 5.
47. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibodyinterleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996; 93: 2702-2707.
48. Pancook JD, Becker JC, Gillies SD, Reisfeld RA. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother 1996; 42: 88-92.
49. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91: 9626-9630.
50. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999; 77: 699-712.
51. Xiang R, Lode HN, Dolman CS, Dreier T, Varki NM, Qian X et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997; 57: 4948-4955.
52. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cellmediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998; 91: 1706-1715.
53. Vile R, Miller N, Chernajovsky Y, Hart I. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Therapy 1994; 1: 307-316.
54. He P, Tang ZY, Liu BB, Ye SL, Liu YK. The targeted expression of the human interleukin-2/interferon alpha2b fused gene in alpha-fetoprotein-expressing hepatocellular carcinoma cells. J Cancer Res Clin Oncol 1999; 125: 77-82.
55. Toloza EM, Hunt K, Swisher S, McBride W, Lau R, Pang S et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther 1996; 3: 11-17.
56. Vaage J. Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities. Cancer Res 1988; 48: 2193-2197.
57. Peterson QP, Hsu DC, Novotny CJ, West DC, Kim D, Schmit JM et al. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Res 2010; 70: 7232-7241.